You have changed your country from  to  . Please be aware that this will change the currency in the purchasing process.

Related products

Reassurance, Refunds & Replacements

If your product does not perform as described on this datasheet, we will refund or replace your product...

Read our guarantee »
 

Anti-KCNQ1 antibody - Carboxyterminal end (ab77701)

CodeSizePriceAbpointsAvailability
    
 
  • -
  •   
  •   
  •   
  •  
  •   
  •   
Updating...

Overview

Product name

Anti-KCNQ1 antibody - Carboxyterminal end
See all KCNQ1 products (5) ...

Description

Rabbit polyclonal to KCNQ1 - Carboxyterminal end

Tested applications

WB, ICC, IHC-FoFrmore details

Cross reactivity

Reacts with

Mouse, Rat, Human

Predicted to work with

Cow, Dog

Immunogen

Synthetic peptide: SNTIGARLNRVEDKVTQLDQ, corresponding to C terminal amino acids 585-604 of Human KCNQ1

SNTIGARLNR VEDKVTQLDQ

Positive control

Adult mouse ventricles.

Properties

Form

Liquid

Storage instructions

Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid repeated freeze / thaw cycles.

Storage buffer

Preservative: 0.1% Sodium Azide
Constituents: 0.1M PBS

Concentration

Concentration information loading...

Purity

Protein A purified

Purification notes

affinity purified

Clonality

Polyclonal

Isotype

IgG

  • Western blot - KCNQ1 antibody - Carboxyterminal end (ab77701)Western blot - KCNQ1 antibody - Carboxyterminal end (ab77701) image (enlarge)

Applications

Show applications key

Our Abpromise guarantee covers the use of ab77701 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application notes

ICC: Use at an assay dependent dilution.
IHC-FoFr: 1/500 - 1/1000.
Note: dilute the antibody in PBS containing 5% normal goat serum, 0.2% Triton X-100 and 0.1% sodium azide.
WB: 1/500 - 1/1000. Detects a band of approximately 72 kDa (predicted molecular weight: 75 kDa).


Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.

Target

Function

Probably important in cardiac repolarization. Associates with KCNE1 (MinK) to form the I(Ks) cardiac potassium current. Elicits a rapidly activating, potassium-selective outward current. Muscarinic agonist oxotremorine-M strongly suppresses KCNQ1/KCNE1 current in CHO cells in which cloned KCNQ1/KCNE1 channels were coexpressed with M1 muscarinic receptors. May associate also with KCNE3 (MiRP2) to form the potassium channel that is important for cyclic AMP-stimulated intestinal secretion of chloride ions, which is reduced in cystic fibrosis and pathologically stimulated in cholera and other forms of secretory diarrhea.

Tissue specificity

Abundantly expressed in heart, pancreas, prostate, kidney, small intestine and peripheral blood leukocytes. Less abundant in placenta, lung, spleen, colon, thymus, testis and ovaries.

Involvement in disease

Defects in KCNQ1 are the cause of long QT syndrome type 1 (LQT1) [MIM:192500]; also known as Romano-Ward syndrome (RWS). Long QT syndromes are heart disorders characterized by a prolonged QT interval on the ECG and polymorphic ventricular arrhythmias. They cause syncope and sudden death in response to exercise or emotional stress. LQT1 inheritance is an autosomal dominant.
Defects in KCNQ1 are the cause of Jervell and Lange-Nielsen syndrome type 1 (JLNS1) [MIM:220400]. JLNS1 is an autosomal recessive disorder characterized by congenital deafness, prolongation of the QT interval, syncopal attacks due to ventricular arrhythmias, and a high risk of sudden death.
Defects in KCNQ1 are the cause of atrial fibrillation familial type 3 (ATFB3) [MIM:607554]. Atrial fibrillation is a common disorder of cardiac rhythm that is hereditary in a small subgroup of patients. It is characterized by disorganized atrial electrical activity and ineffective atrial contraction promoting blood stasis in the atria and reduces ventricular filling. It can result in palpitations, syncope, thromboembolic stroke, and congestive heart failure.
Defects in KCNQ1 are the cause of short QT syndrome type 2 (SQT2) [MIM:609621]. Short QT syndromes are heart disorders characterized by idiopathic persistently and uniformly short QT interval on ECG in the absence of structural heart disease in affected individuals. They cause syncope and sudden death.

Sequence similarities

Belongs to the potassium channel family. KQT (TC 1.A.1.15) subfamily. Kv7.1/KCNQ1 sub-subfamily.

Domain

The segment S4 is probably the voltage-sensor and is characterized by a series of positively charged amino acids at every third position.

Cellular localization

Cell membrane. Cytoplasmic vesicle membrane.

Target information above from: UniProt accessionP51787 The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010).

Information by UniProt

Form

There are 2 isoforms produced by alternative splicing. Isoform 2 also known as: TKvLQT1.

Alternative names

  • ATFB1 antibody
  • ATFB3 antibody
  • FLJ26167 antibody
  • IKs producing slow voltage-gated potassium channel subunit alpha antibody
  • IKs producing slow voltage-gated potassium channel subunit alpha KvLQT1 antibody
  • Jervell and Lange-Nielsen syndrome 1 antibody
  • JLNS1 antibody
  • KCNA8 antibody
  • KCNA9 antibody
  • KCNQ1 antibody
  • KCNQ1_HUMAN antibody
  • kidney and cardiac voltage dependend K+ channel antibody
  • KQT-like 1 antibody
  • Kv1.9 antibody
  • Kv7.1 antibody
  • KVLQT1 antibody
  • long (electrocardiographic) QT syndrome, Ward-Romano syndrome 1 antibody
  • LQT antibody
  • LQT1 antibody
  • Potassium voltage-gated channel subfamily KQT member 1 antibody
  • potassium voltage-gated channel, KQT-like subfamily, member 1 antibody
  • RWS antibody
  • slow delayed rectifier channel subunit antibody
  • SQT2 antibody
  • Voltage-gated potassium channel subunit Kv7.1 antibody
  • WRS antibody
see all

Anti-KCNQ1 antibody - Carboxyterminal end images:

  Western blot - KCNQ1 antibody - Carboxyterminal end (ab77701)

Western blot - KCNQ1 antibody - Carboxyterminal end (ab77701)

All lanes : Anti-KCNQ1 antibody - Carboxyterminal end (ab77701) at 1 µg/ml

Lane 1 : PANC-1 (Human pancreatic carcinoma, epithelial-like cell line) Nuclear Lysate (ab14882)
Lane 2 : A498 (Human Kidney Carcinoma) Whole Cell Lysate

Lysates/proteins at 10 µg per lane.

Secondary
Goat polyclonal Secondary Antibody to Rabbit IgG - H&L (HRP), pre-adsorbed (ab97080) at 1/5000 dilution
developed using the ECL technique

Performed under reducing conditions.

Predicted band size : 75 kDa
Observed band size : 74 kDa (why is the actual band size different from the predicted?)


Exposure time : 150 seconds

References for Anti-KCNQ1 antibody - Carboxyterminal end (ab77701)

ab77701 has not yet been referenced specifically in any publications.

Publishing research using ab77701? Please let us know so that we can cite the reference in this datasheet

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"